Inhibition of Daptomycin by Pulmonary Surfactant: In Vitro Modeling and Clinical Impact
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
The lipopeptide daptomycin has been approved for use in skin and skin-structure infections but has failed to meet statistical noninferiority criteria in a clinical trial for severe community-acquired pneumonia. Daptomycin exhibited an unusual pattern of activity in pulmonary animal models: efficacy in Staphylococcus aureus hematogenous pneumonia and inhalation anthrax but no activity against Streptococcus pneumoniae in simple bronchial-alveolar pneumonia. Daptomycin was shown to interact in vitro with pulmonary surfactant, resulting in inhibition of antibacterial activity. This effect was specific to daptomycin and consistent with its known mechanism of action. This represents the first example of organ-specific inhibition of an antibiotic.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Daptomycin is inhibited by pulmonary surfactant 160 and thus is contraindicated in the treatment of S aureus pneumonia acquired via the aspiration route.”
Citations
Cites
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Medical Entomology and Zoology · Cited by 17,248
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Cited by 16,875
Pulmonary surfactant: functions and molecular composition
Goerke, J. (1998) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(98)00060-x · Cited by 724 · cited 3×
“pulmonary surfactant is different from that of most eukaryotic membranes; it primarily contains PC and only low levels of cholesterol and sphingolipids [3].”
BackgroundInfluentialCorrelation of Daptomycin Bactericidal Activity and Membrane Depolarization in Staphylococcus aureus
Silverman, J. A., Perlmutter, N. G., & Shapiro, H. M. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.8.2538-2544.2003 · Cited by 656 · cited 2×
“molecular synthesis, and cell death [7].”
BackgroundSelf-citationIn Vivo Pharmacodynamic Activity of Daptomycin
Safdar, N., Andes, D., & Craig, W. A. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.1.63-68.2004 · Cited by 370 · cited 1×
“pneumoniae, including skin and soft tissue (thigh) infections [10], meningitis [11], and endocarditis [12], but has specifically failed in a simple model of BAP (table 1).”
BackgroundCarpenter, C. F., & Chambers, H. F. (2004) · Clinical Infectious Diseases · doi:10.1086/383472 · Cited by 358 · cited 1×
“class of antibiotics, the lipopeptides [6].”
Structural Transitions as Determinants of the Action of the Calcium-Dependent Antibiotic Daptomycin
Jung, D., Rozek, A., Okon, M., & Hancock, R. E. W. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.04.020 · Cited by 297 · cited 3×
“Daptomycin is inserted into the membrane of gram-positive bacteria and artificial lipid vesicles [7, 15, 16].”
BackgroundPenetration of Antibiotics into Respiratory Secretions
Pennington, J. E. (1981) · Clinical Infectious Diseases · doi:10.1093/clinids/3.1.67 · Cited by 192
Extraction, Characterization, and Cellular Localization of the Lipids of Staphylococcus aureus
White, D. C., & Frerman, F. E. (1967) · Journal of Bacteriology · doi:10.1128/jb.94.6.1854-1867.1967 · Cited by 184 · cited 1×
“Surfactant is also ∼10% PG, a prominent component of the gram-positive plasma membrane [18].”
BackgroundSakoulas, G., Eliopoulos, G. M., Alder, J. D., & Eliopoulos, C. T. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.5.1714-1718.2003 · Cited by 133 · cited 1×
“pneumoniae, including skin and soft tissue (thigh) infections [10], meningitis [11], and endocarditis [12], but has specifically failed in a simple model of BAP (table 1).”
BackgroundSelf-citation
Cited by
Tong, S. Y. C., Davis, J. S., Eichenberger, E., Holland, T. L., & Fowler, V. G. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00134-14 · Cited by 5,192
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq146 · Cited by 4,191
“Although daptomycin should not be used in patients with pneumonia because of inactivation by pulmonary surfactant [182], it can be used in septic pulmonary emboli [183].”
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232
Antimicrobial Resistance in ESKAPE Pathogens
De Oliveira, D. M. P., Forde, B. M., Kidd, T. J., Harris, P. N. A., Schembri, M. A., Beatson, S. A., Paterson, D. L., & Walker, M. J. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00181-19 · Cited by 2,078
“, tigecycline and daptomycin), which are often associated with increased cost, diminished efficacy, and a greater risk of toxicity compared with the cost, efficacy, and risk of toxicity of first-line antibiotic therapies (Table 1) (49, 50).”
BackgroundMethicillin-resistant Staphylococcus aureus: an overview of basic and clinical research
Turner, N. A., Sharma-Kuinkel, B. K., Maskarinec, S. A., Eichenberger, E. M., Shah, P. P., Carugati, M., Holland, T. L., & Fowler, V. G. (2019) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0147-4 · Cited by 2,051
Metadata
- Authors
- Silverman, J. A., Mortin, L. I., VanPraagh, A. D. G., Li, T., & Alder, J.
- Affiliations
- Cubist Pharmaceuticals (United States) (US)
- Corresponding author
- Silverman, Jared A.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-06-15
- Volume
- 191
- Issue
- 12
- Pages
- 2149-2152
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2108525727
- Cited by
- 541
- References
- 18
- Citations by year
- 2026: 17 · 2025: 14 · 2024: 25 · 2023: 18 · 2022: 23 · 2021: 23 · 2020: 18 · 2019: 20 · 2018: 24 · 2017: 24 · 2016: 20 · 2015: 24 · 2014: 22 · 2013: 25 · 2012: 28
- FWCI
- 23.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Epidemiology › Pneumonia and Respiratory Infections
- Life Sciences › Immunology and Microbiology › Microbiology › Antimicrobial Peptides and Activities
- Keywords
- daptomycin, pulmonary surfactant, antibiotic inhibition, lipopeptide antibiotics, Staphylococcus aureus, Streptococcus pneumoniae, community-acquired pneumonia, inhalational anthrax, antibiotic-drug interactions
- MeSH terms
- Animals, Anti-Bacterial Agents, Lung, Microbial Sensitivity Tests, Pneumococcal Infections, Pulmonary Surfactants, Staphylococcal Infections, Daptomycin, Pneumonia, Bacterial, Drug Resistance, Bacterial, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.